RespireRx Pharmaceuticals Inc (fka RSPI)

[Aiming4]

Neuro - I meant to cover the pipeline breadth issue when I said this: "and to cover the time gap after Cortex would have out-licensed their lead molecules to BP partners".

Even with the pipeline angle originally being the greater part of the reason for the in-licensing, do you think the obvious push by Cortex to get the in-licensing done by Q2 has anything to do with Cortex wanting to be sure they have a Phase II program in hand on the (hopefully very small) chance the FDA returns a bad decision on CX-717?... Aiming4.